Role of Mitochondrial Dysfunction in Insulin Resistance
线粒体功能障碍在胰岛素抵抗中的作用
基本信息
- 批准号:7676040
- 负责人:
- 金额:$ 24.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:1-Phosphatidylinositol 3-KinaseATP Synthesis PathwayAcyl Coenzyme AAddressAgeArtsBiogenesisBiopsy SpecimenBrainCategoriesCitric Acid CycleConditionDataDefectDevelopmentDiabetes MellitusDiseaseDyslipidemiasEnergy MetabolismEventFast-Twitch Muscle FibersFatty AcidsFiberFirst Degree RelativeGenesGoalsHeparinHepaticHyperlipidemiaHypertensionIndividualInfusion proceduresInsulinInsulin ResistanceIsoleucine-Specific tRNALipidsLiverMAPK8 geneMagnetic Resonance SpectroscopyMethodsMitochondriaMuscleMutationNon-Insulin-Dependent Diabetes MellitusParentsPathogenesisPathologicPatientsPhosphorylationPhosphotransferasesPlasmaPlayPrincipal InvestigatorProductionProtein KinaseProtein Kinase CProtein-Serine-Threonine KinasesRateResearch PersonnelRiskRodentRoleSerineSkeletal MuscleSoleus MuscleSpectrum AnalysisTechniquesTherapeutic AgentsTransfer RNATriglyceridesTyrosine PhosphorylationWeightcohortdensitydiabeticfallsfatty acid metabolismglucose transporthuman studyinsightinsulin sensitivityinsulin signalingintrahepaticmicrochipmitochondrial dysfunctionnovelnovel therapeuticspatient orientedpreventprograms
项目摘要
Over ninety percent of diabetics fall into the category of type 2 diabetes and while the primary factors causing this disease are unknown it is clear that insulin resistance plays a major role in its development.
Furthermore insulin resistance is the best predictor for the later development of diabetes. Recent preliminary studies by our group have implicated increases in intramyocellular lipid content due to mitochondrial dysfunction as a major factor in causing insulin resistance in skeletal muscle of offspring of parents with type 2 diabetes (IR offspring). The overall goal of this project is to determine the rote of mitochondrial dysfunction in the pathogenesis of insulin resistance in IR offspring. This will be done using state-of-the-art magnetiq resonance spectroscopy in combination with GC-MS and LC/MS/MS techniques. The specific aims that will be addressed in this patient oriented project are to: 1) Assess mitochondrial function by 13C/31P MRS in skeletal muscle of young lean insulin resistant offspring of parents with type 2 diabetic subjects and ageweight-activity-matched control subjects, 2) Assess mitochondrial density, insulin signaling, IRS-1 serine phosphorylation status, protein kinase Cbeta activation, IKKbeta activation, JNK1 activation, fatty acyl CoA concentrations in muscle biopsy samples obtained from young lean insulin resistant offspring of parents with type 2 diabetic subjects and age-weight-activity-matched control subjects, 3) Assess mitochondrial function by 13C/31P MRS in liver of young lean insulin resistant offspring of parents with type 2 diabetic subjects and
age-weight-activity-matched control subjects, 4) Assess mitochondrial function by 13C/31P MRS in skeletal muscle of patients with hypertension and hyperlipidemia due to a novel homoplasmic mitochondrial tRNA/ile mutation (identified by R. Lifton) and age-weight-activity matched control subjects. It is anticipated that the results of these studies will yield new and important insights into the role of mitochondrial dysfunction and resultant dysregulation of intramyocellular fatty acid metabolism in the pathogenesis of insulin resistance in offspring of parents with type 2 diabetes. This information will enable the rational development of novel therapeutic agents to prevent or reverse this pathologic condition.
超过90%的糖尿病患者属于2型糖尿病类别,尽管引起该疾病的主要因素尚不清楚,但很明显,胰岛素抵抗在其发育中起主要作用。
此外,胰岛素抵抗是后来糖尿病发展的最佳预测因子。我们小组的最新初步研究暗示,由于线粒体功能障碍,由于线粒体功能障碍而导致2型糖尿病(IR后代)父母后代的骨骼肌的胰岛素抵抗的主要因素增加,这意味着导致胰岛素抵抗的主要因素。该项目的总体目标是确定IR后代胰岛素抵抗发病机理中线粒体功能障碍的死记硬背。这将使用最新的磁磁共振光谱与GC-MS和LC/MS/MS技术结合完成。 The specific aims that will be addressed in this patient oriented project are to: 1) Assess mitochondrial function by 13C/31P MRS in skeletal muscle of young lean insulin resistant offspring of parents with type 2 diabetic subjects and ageweight-activity-matched control subjects, 2) Assess mitochondrial density, insulin signaling, IRS-1 serine phosphorylation status, protein kinase Cbeta activation, IKKbeta activation, JNK1 activation, fatty acyl CoA concentrations in muscle biopsy samples obtained from young lean insulin resistant offspring of parents with type 2 diabetic subjects and age-weight-activity-matched control subjects, 3) Assess mitochondrial function by 13C/31P MRS in liver of young lean insulin resistant offspring of parents with type 2 diabetic subjects and
年龄重量活性匹配的对照受试者,4)由于新型的同质性线粒体tRNA/ILNA突变(由R. LIFTON鉴定)和年龄率效率与对照受试者相匹配,因此在患有高血压和高脂血症患者的骨骼肌中评估了13C/31p MRS的线粒体功能。可以预料,这些研究的结果将对线粒体功能障碍的作用以及对2型2型糖尿病型父母的胰岛素抵抗的发病机理的发病机理产生新的重要见解。这些信息将使新型治疗剂的合理发展能够预防或扭转这种病理状况。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GERALD I SHULMAN其他文献
GERALD I SHULMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GERALD I SHULMAN', 18)}}的其他基金
Yale Center for Metabolic Phenotyping in Live Models of Obesity and Diabetes
耶鲁大学肥胖和糖尿病活体模型代谢表型中心
- 批准号:
10579071 - 财政年份:2023
- 资助金额:
$ 24.84万 - 项目类别:
Development of Controlled Release Mitochondrial Protonophore (CRMP) as a Novel Treatment for Type-2 Diabetes and Non-Alcoholic Steatohepatitis in Dysmetabolic Non-Human Primates
开发控释线粒体原细胞 (CRMP) 作为代谢失调的非人类灵长类动物 2 型糖尿病和非酒精性脂肪性肝炎的新型治疗方法
- 批准号:
9894796 - 财政年份:2019
- 资助金额:
$ 24.84万 - 项目类别:
Development of Controlled Release Mitochondrial Protonophore (CRMP) as a Novel Treatment for Type-2 Diabetes and Non-Alcoholic Steatohepatitis in Dysmetabolic Non-Human Primates
开发控释线粒体原细胞 (CRMP) 作为代谢失调的非人类灵长类动物 2 型糖尿病和非酒精性脂肪性肝炎的新型治疗方法
- 批准号:
10352445 - 财政年份:2019
- 资助金额:
$ 24.84万 - 项目类别:
Glucagon Regulation of Hepatic Mitochondrial Activity and Glucose Metabolism by InsP3R-1
InsP3R-1 对肝线粒体活性和葡萄糖代谢的胰高血糖素调节
- 批准号:
10093992 - 财政年份:2018
- 资助金额:
$ 24.84万 - 项目类别:
Effects of Hepatic Acetyl-CoA Carboxylase Inhibition on NAFLD and Hepatic Insulin Resistance
肝乙酰辅酶 A 羧化酶抑制对 NAFLD 和肝胰岛素抵抗的影响
- 批准号:
9763549 - 财政年份:2017
- 资助金额:
$ 24.84万 - 项目类别:
Effects of Hepatic Acetyl-CoA Carboxylase Inhibition on NAFLD and Hepatic Insulin Resistance
肝乙酰辅酶 A 羧化酶抑制对 NAFLD 和肝胰岛素抵抗的影响
- 批准号:
9361162 - 财政年份:2017
- 资助金额:
$ 24.84万 - 项目类别:
Effects of Hepatic Acetyl-CoA Carboxylase Inhibition on NAFLD and Hepatic Insulin Resistance
肝乙酰辅酶 A 羧化酶抑制对 NAFLD 和肝胰岛素抵抗的影响
- 批准号:
10217114 - 财政年份:2017
- 资助金额:
$ 24.84万 - 项目类别:
Genetic and Cellular Mechanisms of NAFLD and Hepatic Insulin Resistance
NAFLD 和肝胰岛素抵抗的遗传和细胞机制
- 批准号:
8545824 - 财政年份:2010
- 资助金额:
$ 24.84万 - 项目类别:
相似国自然基金
基于电子传递链磷酸化途径研究Rnf复合物调控瘤胃丁酸弧菌ATP合成的机理
- 批准号:32202708
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于ATP等辅因子调控的环磷酸腺苷异源合成途径构建
- 批准号:21506097
- 批准年份:2015
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
相似海外基金
The effect of mitochondrial CoA degradation on glucose and fatty acid metabolism
线粒体CoA降解对葡萄糖和脂肪酸代谢的影响
- 批准号:
9891848 - 财政年份:2019
- 资助金额:
$ 24.84万 - 项目类别:
The effect of mitochondrial CoA degradation on glucose and fatty acid metabolism
线粒体CoA降解对葡萄糖和脂肪酸代谢的影响
- 批准号:
9756835 - 财政年份:2019
- 资助金额:
$ 24.84万 - 项目类别:
Role of Protein Malonylation in Regulating Mitochondrial Function
蛋白质丙二酰化在调节线粒体功能中的作用
- 批准号:
9049922 - 财政年份:2015
- 资助金额:
$ 24.84万 - 项目类别:
Regulation of Mitochondrial Dysfunction and Diet-Induced Obesity by ALCAT1
ALCAT1 对线粒体功能障碍和饮食引起的肥胖的调节
- 批准号:
8288795 - 财政年份:2008
- 资助金额:
$ 24.84万 - 项目类别:
Regulation of Mitochondrial Dysfunction and Diet-Induced Obesity by ALCAT1
ALCAT1 对线粒体功能障碍和饮食引起的肥胖的调节
- 批准号:
7657500 - 财政年份:2008
- 资助金额:
$ 24.84万 - 项目类别: